Multiobjective Optimization Applied to the Eradication of Persistent Pathogens by Steuernagel, O. & Polani, D.
IEEE TRANSACTIONS ON EVOLUTIONARY COMPUTATION, VOL. 14, NO. 5, OCTOBER 2010 759
Multiobjective Optimization Applied to the
Eradication of Persistent Pathogens
Ole Steuernagel and Daniel Polani
Abstract—In scenarios such as therapeutic modeling or pest
control, one aims to suppress infective agents or maximize crop
yields while minimizing the side-effects of interventions, such
as cost, environmental impact, and toxicity. Here, we consider
the eradication of persistent microbes (e.g., Escherichia coli,
multiply resistant Staphylococcus aureus (MRSA-“superbug”),
Mycobacterium tuberculosis, Pseudomonas aeruginosa) through
medication. Such microbe populations consist of metabolically
active and metabolically inactive (persistent) subpopulations. It
turns out that, for efficient medication strategies, the two goals,
eradication of active bacteria on one hand and eradication of
inactive bacteria on the other, are in conflict. Using multiobjective
optimization, we obtain a survey of the full spectrum of best
solutions. We find that, if treatment time is limited and the total
medication dose is constant, the application of the medication
should be concentrated both at the beginning and end of the
treatment. If the treatment time is increased, the medication
should become increasingly spread out over the treatment period
until it is uniformly spread over the entire period. The transition
between short and long overall treatment times sees optimal
medication strategies clustered into groups.
Index Terms—Biochemistry, biological systems, biology,
biomedical, chemistry, computational bioinformatics, computa-
tional intelligence, ecology, evolutionary biology, evolvable hard-
ware, game theory, mathematics.
I. Introduction
A. Problem of Bacterial Persistence
NOT ONLY hibernating mammals or sporing fungi reduceor stop their metabolic activities, also some microbial
organisms are known to randomly slip into and out of
“hibernation.” This is essentially characterized by reduced
metabolic activity and reduced or suspended reproduction. The
disadvantage of reduced population growth, goes hand-in-hand
with the advantage of reduced vulnerability to drugs, rendering
“hibernating” bacteria persistent in the face of medication
treatments [2], [8], [12], [17], [19]. Bacterial population can
therefore consist of genetically identical active and persister
subpopulations.
From a human point of view, be it medical or pest control,
the presence of persisters can have serious consequences.
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Bacterial persistence was first observed in Staphylococcus
when, in 1944, Bigger [2], [12] noted that penicillin did not
always kill all exposed bacteria although sufficient toxicity
was established. Based on the observation that bacteria sur-
viving penicillin treatment were no less susceptible than their
ancestors, it was concluded that heritable bacterial resistance
was not involved but persistent behavior could explain such a
finding; this has recently been reconfirmed [2].
Bacterial persistence can occur irrespective of environmen-
tal conditions [2], [17] and is widespread [2], [7], [8], [11],
[12], [16], [17]. It also appears in viruses, which can become
persistent by integrating into their host’s genome and suspend-
ing production of virus particles, as exemplified by human
immunodeficiency virus (HIV), herpes, and the bacteriophage
lambda.
The tradeoff between the persisters’ growth-underper-
formance under benign conditions on one hand, and the
wipeout of all active organisms in the case of a catastrophe on
the other, leads to a small random subpopulation of persisters
individually “bet-hedging” to switch into a persistent state
[9] thus effectively establishing a “life-insurance” [13], [14].
Persistence can bring a species “back from the brink,” even
when sequences of sudden catastrophes occur, because, in all
likelihood, a few persisters will have stayed out of harm’s way
[14]. It is thus relevant in disease prevention [12] and requires
new treatment regimes [19]. Escherichia coli (E. coli), MRSA-
“superbug”, Mycobacterium tuberculosis, and Pseudomonas
aeruginosa show persistence [2], [12], [17], possibly extending
to airborne infectants [11]. Persistence also appears to be
important in ecological scenarios [7], [16] and latent HIV-1
infections [8].
In E. coli, the conversion rate from the active subpopulation
to the persistent form and the reverse rate have been shown
to be independent of environmental factors [2], [12]. In other
words, no sensorial input about the quality of the environment
is used to trigger the conversion from one to the other. In
this paper, we only consider this type of persistence. It is an
effective strategy for organisms, which face life in environ-
ments where sudden devastating degradation and recovery is
an acute possibility and moreover dispenses with the need to
maintain sensors for surveying the environment—an important
advantage for primitive organisms [14].
B. Our Approach
In this paper, we primarily intend to highlight the fea-
tures of multiobjective optimization and its applicability to
1089-778X/$26.00 c© 2010 IEEE
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problems in the life sciences. Our model for the eradication
of persistent pathogens shows that eradication of persisters and
normal pathogens form conflicting objectives which are best
approached using multiobjective optimization. Our model is
not intended to quantitatively represent a specific biological
or clinical system but to investigate the problem in general
terms. Multiobjective optimization [4] has been rarely applied
to problems in the life sciences [10], [15]. It is, however,
becoming clear that the benefits of using multiobjective op-
timization in the life sciences could be considerable [10].
We adopt population dynamical models based on coupled
differential equations [2], [13], [14], [17] for the numerical
study of the behavior of persistent pathogens exposed to
different medication strategies (we use the terms “medication”
and “drug” interchangeably, they stand for the presence of
any hazardous entity killing the pathogens, such as radiation,
chemicals, antibodies, etc.).
We assume that only two subpopulations are present, active
(normal) pathogens that grow at a normal rate, and are
susceptible to the medication, and persisters (such as type II
in [2]) that grow more slowly and are less susceptible. We
assume that the subpopulations are so large that discreteness
of population sizes can be neglected. we denote the sizes
of the normal and the persistent subpopulations by the time-
dependent functions, n(t) and p(t), respectively. This contin-
uous description allows us to employ continuous differential
equations (in the “deterministic limit” [13]) which are readily
integrated using a computer.
Initially, we will confirm mathematically that the best
approach to the eradication of nonpersistent multiplying
pathogens is their immediate extermination by as strong a
medication dose as possible. Whereas this case is intuitively
easy to understand, matters become much more complicated
when persistence is taken into account.
The slowdown or shutdown of the persisters’ metabolism
protects them from medication. One therefore has to retain
some medication to be administered some time after the first
dose of medication was applied. This helps to exterminate
persistent pathogens that have bypassed the biocidal effects of
the initially given medication and subsequently revert back to
their active state.
For such followup action neither very long waiting times
are allowed, because the surviving active pathogens multiply
and thus hurt the host and replenish the persisters’ reservoir,
nor is immediate followup medication advised; otherwise the
persisters have not had enough time to come out of the
persistent state and so the medication hurts the host more than
the pathogens.
Neither intuitive nor analytical solutions for this problem
are available, we therefore choose a model in which a course
of treatment consists of the administration of N equal units
of the drug (we choose N = 10). The total amount of drug
applied during a course of treatment is fixed. The course of
treatment extends over a fixed time interval, spanning from the
initial time t = 0, of the pathogens’ detection, to the time t = T
when the final outcome of the treatment is evaluated. Within
this interval, times for the individual drug administrations tk,
with (k = 1, ..., N), are chosen freely. Different medication
scenarios, i.e., the effect of different distributions of the N
administration times {tk} are compared for their effectiveness.
The objective of the treatment is the minimization of the sizes
of the normal, n(T ), and the persistent subpopulation, p(T ),
at the end of the course of treatment.
Although we perform multiobjective optimization we fix
this treatment time, T , beforehand. One can, of course, gen-
eralize our approach to include variable treatment times as
well, thus having to consider three objective variables, namely,
n(T ), p(T ), and T . Then, our problem space would be 3-D
and the set of best solutions would form a complicated
2-D hypersurface embedded in it: too rich a system for an
introductory treatment of our method. We thus consider a 2-D
problem space [n(T ), p(T )] and the family of best solutions
that form a 1-D hypersurface within.
We will, toward the end of this paper consider the general
trends of our model system’s behavior when the total treatment
time T is varied as well.
Aside from this simplicity issue, there are two more good
reasons to fix the total treatment time T beforehand.
We assume that cumulative toxicity of the medication is the
major constraint regarding its application (this is reasonable
for scenarios, such as radiation therapy, many types of medica-
tion treatments and for agricultural and other such environmen-
tal scenarios). With a cumulative dosage constraint, medication
strategies must not be drawn out too much in time since
the medication becomes overdiluted, see below. We therefore
arrive at a natural upper limit for the total treatment time T .
If there is no time constraint, and if one makes sure
that the medication does not become overdiluted, drawn out
medication regimes where the medication is administered at
a constant rate throughout the treatment T show the greatest
suppression of n(T ) and p(T ), see Fig. 3. But this kind of
treatment regime can become unstable due to the danger of
overdilution (see caption of Fig. 3) and is also harder to adhere
to than treatment regimes of fixed shorter time.
In light of the fact that imperfect patient adherence to
medication strategies is of considerable concern [1], we thus
conclude that there are the following reasons to consider fixed
total treatment times T : simplicity, safety, and practicality.
C. Problem Space and the Pareto Front
Different medication strategies lead to different final results.
When the times at which a medication dose is administered
is continuously changed the outcome changes continuously as
well. Therefore, the problem space consists of a connected area
of feasible solutions outside of which lies the region which
cannot be reached by any feasible solution; because, say,
perfect or near perfect suppression of the pathogens’ numbers
is beyond the eradication power of the medication. An example
in our model would be the origin [n(T ), p(T )] = [0, 0] and
its immediate neighborhood. This area cannot be reached
because the differential equations used in our model only allow
for exponential suppression of the population, not complete
eradication (on the issue of complete extermination due to
fluctuations see [13]).
The most interesting area is the boundary that lies between
feasible and unfeasible solutions for small numbers of n(T )
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and p(T ), because it contains the optimal cases of what is
feasible. The boundary can have a complicated shape, see, for
instance, Figs. 10 and 13 of [18].
The Pareto front contains all those points of the boundary
for which there are no other points which allow for solu-
tions that are simultaneously better or equal with respect to
all optimization objectives; it only contains “nondominated”
solutions. Since the boundary can have a complicated form,
the subset of Pareto-optimal points can be discontinuous, see
Figs. 11(c) and 14(b) of [18]. Typically, a continuous Pareto
front in 2-D has a shape like the curve shown in Fig. 2(b),
also, compare Figs. 9, 10, and 13 in [18].
In principle, using conventional single-objective optimiza-
tion and changing all available relative weight factors that
were used to combine several objectives artificially into a
single one allows us to find the Pareto front as well [18].
However, for practical reasons this modification of single-
objective optimization is unfeasible because many solutions
are being entirely missed, see Fig. 14(c) of [18]. Using
multiobjective optimization allows us to gain the advantage of
being able to explore the entire set of optimal solutions [18].
D. Our Model
For transparency we also employ the following simplifica-
tions.
The active subpopulation, n(t), grows at a constant rate µn
leading to exponential growth, whereas the persisting sub-
population, p(t), grows at a substantially lower rate µp [13]
which we set to zero for simplicity (without affecting our basic
conclusions). We, similarly, neglect the (greatly reduced) kill
rate of persisters in the presence of medication [2], [3].
The subpopulations convert into each other at constant
rates a and b [2], [13], although these rates may depend
on environmental conditions [9]. We assume that only the
active subpopulation is being decimated by the medication:
we assume its power to kill to be proportional to the drug
concentration, c(t), [3] (although nonlinear threshold behavior
has been observed as well [3]—in which case other assump-
tions such as zero growth of the persisters may have to be
reviewed). We therefore arrive at the following system of
coupled ordinary differential equations for the behavior of the
subpopulations as functions of time
d n(t)
dt
= (µn − c(t) − a) · n(t) + b · p(t) (1)
d p(t)
dt
= a · n(t) − b · p(t). (2)
E. Our Assumptions
In what follows we will assume that the total administered
medication dose is fixed. This assumption is motivated by the
cumulative toxicity of medical treatments. Our approach can
be adapted accordingly, if avoidance of peak values of the drug
concentration is the primary concern.
In general, the concentration of the drug, c(t), could be given
by any nonnegative function. In accord with our approach,
we model each administered drug dose by the same Gaussian
peaks (bell-shaped curves) with equal strength D0, centered
on the respective administration times tk, a treatment course,
D(t), is thus described by the sum
D(t) =
N∑
k=1
D0
exp
[
−(t−tk)2
σ2
]
√
πσ
. (3)
Here σ scales the widths of the Gaussians (compare Fig. 1)
and the normalization factor 1/(√πσ) assures that each peak
is of unit strength (∫∞−∞ dt exp
[
−(t−tk)2
σ2
]
/(√πσ) = 1).
We assume that the drug is cleared out of the system at a
constant rate R (in units of h−1), its concentration, c(t), thus
obeys the differential equation
d c(t)
dt
= D(t) − R c(t). (4)
For the drug concentration this yields
c(t) = c0 +
∫ t
0
dτ D(τ) e−R(t−τ) (5)
with the assumed initial value c0 = 0, i.e., no medication is
present before the treatment starts at time zero. Note that small
values of the drug-clearance rate R lead to prolonged presence
of the medication and thus to a greater cumulative effect since
the accumulated medication dose
C(T ) =
∫ T
0
dt c(t) (6)
scales with R−1, just like the total integrated dose
C∞
.
=
∫ ∞
−∞
dt
∫ t
−∞
dτ D(τ)e−R(t−τ) = N D0 /R . (7)
This expression C∞ ignores the initial value assumption c0 = 0
and therefore has a simple and transparent form. Because it
includes the small tails of the medication distribution extend-
ing beyond of the treatment time interval [0, T ] it slightly
overestimates the value of the total cumulative administered
dose, C(T ).
Scenarios that can be described by (1) and (2) include
a bacterial infection by a persistent species which is being
fought with drugs [term “−c(t) · n(t)” in (4)] where the drug
degrades over time [say, by excretion, aging, or evaporation:
term “e−R(t−τ)” in (7)].
Note that our assumption regarding a finite number of
administered doses N, in (3), is the generic way in which
medication is released (in radiation treatment or pest control
with agricultural aircraft, continuous administration may be
altogether unfeasible). Continuous medication (drip-feed) can
easily be emulated with our model using a large number, N,
of doses shots.
Without medication (c(t) = 0) the system (1)–(2) has
constant coefficients and is therefore analytically solvable
with the general solution [n(t), p(t)] = w+e+ exp[λ+t] +
w−e− exp[λ−t]. Here, the two eigenvector e± = [µn − a +
b ±
√
(a + b)2 + µn(µn − 2a + 2b), 2a] are associated with
eigenvalues λ± = [bµn ±
√
b2µ2n + 4(µn − b − a)]/2. The
component w+e+ will quickly outgrow its counterpart w−e−
because λ+ > λ−. The wild-type without the influence of
medication is therefore typically well described by the state
w+e+ exp[λ+t]. This implies that the generic initial ratio of
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Fig. 1. Response of pathogen population to medication. (a) Drug concen-
tration, c(t), as a function of time. N = 7 dose units, of strength D0 = 430
each, are administered at times 1 h, 1.5 h, 2 h, 4 h, 4.5 h, 5 h, 8 h. The widths
of the peaks is σ = 0.2 h and the drug-clearance rate is R = 2 h−1. (b) Time
evolution of active organisms n(t) (red solid line) and persisters p(t) (blue
dotted line) with parameters µn = 20 h−1, a = 0.5 h−1 and b = 0.5 h−1, note
that the persister responses are delayed in time.
active to persistent pathogens is given by the ratio of the
components of the wild-type e+, namely
n(0)
p(0) =
µn + b − a +
√(b + a)2 + 2µn(b − a) + µ2n
2a
. (8)
We therefore choose n(0) = 1 and p(0) in accordance with (8)
as a natural initial condition which models pathogens found
in their natural infection habitat. If they are found under very
different circumstances, such as bacteria residing in a bacterial
biofilm, the initial fraction of persisters can be much higher
[12] than assumed here.
II. Results
Equations (1) and (2) do not, in general, allow for an ana-
lytical solution. This is why we investigate them numerically.
A typical scenario is portrayed in Fig. 1. It illustrates that
active organisms, n(t), primarily get killed by the medication
whereas the inactive ones, p(t), primarily suffer losses due
to conversion into active ones and regain numbers when the
active ones recover. The two subpopulations sustain each other.
The goal is to push the entire pathogen population toward
its possible extinction (i.e., to such small numbers that action
of the host’s immune system or random fluctuations can wipe
it out [13]).
A. Fighting Nonpersistent Pathogens
Without persistence all pathogens are affected by the med-
ication and should be killed immediately. This can be shown
formally: assuming the infection is discovered at time zero, an
integration of (1) yields n(T ) = n(0) exp[∫ T0 (µn − c(τ))dτ] =
n(0) · eE(T ), where the effective exponent
E(T ) = µn · T − C(T ) (9)
contains the accumulated medicine dose, C(t), of (6). Maximal
suppression of the pathogen population requires the largest
achievable negative values of E(T ): the positive growth term
“µn · T ” has to be minimized. This shows the medication has
to be given immediately.
The effective exponent also yields the condition, E(T ) = 0,
which estimates where the medication just balances pathogen
growth. Assuming, as above, that C(T ) ≈ C∞, we find that
for values of T surpassing
Tmax =
ND0
µnR
. (10)
E(T ) becomes positive and pathogen growth is no longer
kept in check. A fixed total dosage C∞ thus implies a natural
constraint on the total treatment time beyond which drug
overdilution renders treatments ineffective.
B. Fighting Persistent Pathogens: Pareto Front
Transition into and out of the persistent state (a, b > 0)
allows pathogens to avoid the effects of medication and
shortens the effective maximal stalemate-time considerably,
thus our estimate for Tmax, derived for the case of nonpersisting
pathogens, only establishes an upper bound on the permissable
total treatment time for an effective treatment of persisters.
Due to their persistence (a, b > 0) pathogens show a
delayed response [2] (compare Fig. 1) which complicates their
eradication. We now compare different eradication strategies.
First, values for D0 and R (keeping the total effective dose C∞
constant), and a fixed total treatment time T are chosen.
Then we vary the (ten) medication times ({tk}, k = 1, ..., 10)
thus modifying the dosage strategies [choice of time-points
tk ∈ [0, T ] in (3)]. Upon integration of (1) and (2), using the
fourth order Runge–Kutta method, we determine the number
of survivors n(T ) and p(T ) as our quality criterion.
The delayed response leads to a tradeoff between eradication
of active versus persister subpopulations, this complicates the
analysis; without further assumptions a best treatment strategy
cannot be identified. To map out the solution space, we
therefore perform multiobjective optimization [4], using the
nondominated sorting genetic algorithm (NSGA)-II [6]. We
determine the set of Pareto-optimal strategies: in an n(T )-
over-p(T ) plot they form a Pareto-optimal front [4] of points
corresponding to dosage strategies that lead to simultaneously
minimized (nondominated) final values of n(T ) and p(T ).
For the integration of the differential equation, we use a
regular fourth-order Runge–Kutta integrator, with a step length
of t = 0.01. The integration was found to provide consistent
results for all runs up to a step length of at least t = 0.015,
thus ensuring numerical stability of the employed integration
routine.
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Fig. 2. Typical example of optimal treatment strategies. Treatment time T =
30 h, bacterial parameters of E. coli wild-type [13] (except for our choice
of µp = 0): µn = 2 h−1, a = 1.2 × 10−6 h−1, b = 0.1 h−1. We choose
n(0) = 1 and p(0) ≈ 5.714 × 10−7 in accord with the natural initial
condition (8). Medication parameters D0 = 100, N = 10, σ = 10 h and
R = 0.2 h−1. (a) Pareto front of optimal strategies shows the tradeoff between
suppressing active and persister subpopulations. The response margin for
suppressing persisters is relatively much narrower than that for suppressing
active pathogens (the spread of values on the horizontal coordinate axis is
small). (b) Same treatment regimes, plot displays dose number k administered
at time tk over total time t and index m (representing the solution number—
out of 100) of solutions found by the NSGA-II algorithm sorted with respect
to increasing values of surviving persisters p(t). Note the emergence of
distinct steps separating groups of treatment regimes despite a large value
of σ (this distinction becomes clearer still for smaller values of σ). The color-
and symbol-coding matches subsections of the Pareto front in (a) with the
treatment regimes displayed in (b).
The NSGA-II multiobjective optimization algorithm [6]
with a population size of 100 was used, running for 500
generations, using the final populations n(T ) and p(T ) as the
two objectives. The objectives were constrained to nonnegative
values to prevent the genetic algorithm from being caught in
spurious numerical instabilities. The algorithm optimized the
medication times {tk} (k = 1 . . . 10 in our case), the crossover
probability was set to 0.9 and the mutation probability to 0.1.
The parameters ηc and ηm for the polynomial distributions
used in the SBX crossover and in the mutation operator [5],
[6], were both set to 16.
The precise choice of these parameters turned out to be
uncritical. We found that the results reported below are robust
with respect to variations of crossover and mutation probabil-
Fig. 3. Collection of several Pareto fronts for various treatment times T
shows increased effectiveness of longer treatments. Same parameters as in
Fig. 2 except for treatment times ranging from T = 10 h, . . . , 500 h, see
legend. We observe breakdown of treatment at T ≈ 600 h (not shown) because
medication becomes too much diluted.
ities from 0.01 to 0.99, similarly the ηc and ηm parameters
could be varied between 1.6 and 160 without affecting the
position of the Pareto front. Typically, the essential features of
the Pareto front emerged reproducibly after approximately 50
generations, whereas the remainder of the run served to fine-
tune the precise features of the front and the corresponding
solutions. Only for extreme choices of the parameters, namely
crossover and mutation probabilities equal to 0.01 and very
narrow SBX characteristics, ηc = 160, ηm = 160, was the
extent of the Pareto front covered significantly more slowly;
apart from such extreme choices only insignificant perfor-
mance differences could be observed.
We now discuss the features of the solutions in detail.
At one end of the Pareto front one finds the strongest
suppression of persisters, at the other end the strongest sup-
pression of active bacteria, compare Fig. 2(a).
Fig. 2(b) shows that a strategy aiming to suppress
the persistent subpopulation requires early administering of
large doses of medication. This is due to the fact that the
active population has to be suppressed early on and then some
medication has to be used to hold the persister’s in check
that are “waking up” and become active again. Alternatively,
when the primary strategic aim is the suppression of the active
subpopulation or a mixed strategy, a later application of the
bulk of the medication is advised, although (depending on
details) some medication should also be given at the start
(as soon as the infection is discovered). Associated optimal
strategies may therefore be very different from strategies
which aim for uniform constant exposure to medication, or,
from the “kill before they multiply” strategy described above.
One should note the emergence of discrete “bands” of optimal
strategies in Fig. 2(b).
Although the relative population suppression factor due to
the medication treatment may be satisfactory in the example
sketched in Figs. 2(a) and 3, we are clearly most interested
in the critical cases where (because of cost, toxicity, or other
reasons) the treatment is in danger of failing. In this context,
it should be pointed out that, worryingly, the narrow response
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margin of final persister subpopulations p(T ) is a generic
feature (see Fig. 2). We are thus led to consider a variation
of the total treatment time T as well. Fig. 3 displays several
Pareto fronts for different values of T . Each individual front
shares the features displayed in Fig. 2. Overall, there is a
trend to more effective treatments with lengthened treatment
time in which case the medication has to be administered
more uniformly over the entire treatment period. It must
not be lengthened too much though, because the medication
would become too diluted (see discussion leading up to
expression (10) above).
III. Discussion
The overall treatment time T has to be sufficiently long
to kill persisters which are protected by the time lag in the
pathogens’ response dynamics but short enough not to dilute
the medication concentration too much. If short treatment
times can yield sufficient pathogen suppression, the use of
such strategies may well be safer, since they lead us away
from a possible breakdown due to overdilution.
Also, as one shortens T , the characteristics of optimal strate-
gies change: instead of being uniformly distributed over T ,
doses are typically increasingly concentrated at the beginning
and/or end of the treatment time, compare Fig. 2(b). Such
strategies do not only need less time than drawn out therapies,
but they are also simpler to administer. We believe that in
view of widespread problems with patient adherence to long
lasting medication regimens [1] such optimized strategies may
offer relevant alternatives that deviate from current clinical
practice. In this context, we would like to point out that these
treatment regimes appear to be quite stable with respect to
small changes in strategy, such as completely concentrating
all medication toward beginning and end of the treatment
period. In other words, a judiciously dosed two-shot approach,
almost the simplest conceivable strategy, can yield nearly
optimal results, is shorter than a maximally drawn out ther-
apy and not in danger of failure due to overdilution of the
medication.
For sufficiently large medication doses, the qualitative re-
sults reported above also apply to the case of amplified
persistence (as is the case for the high persistence (hip)
mutants of E. coli analyzed in Balaban et al. [2]). When
persistence is increased, but a simultaneous increase in med-
ication is impossible, the results can change dramatically.
An eradicable disease can become unstoppable. To illustrate
this point, we compare the response of the wild-type of
E. coli, Fig. 3, with its highly persistent hipQ-type twin [2],
[13] in Fig. 4. We assume the two to be identical except
for their different persistence rates a and b [13]. Under
identical treatment and initial conditions as for the wild-
type, we let the search algorithm find the modified Pareto
front. Fig. 4 shows that short, highly concentrated treatments
allow us to suppress the active subpopulation but they are
too short to affect the persisters. For longer treatments, the
persisters’ reflux rate b, back to the normal state, is still too
low to deplete them sufficiently, the pathogen has become
untreatable.
Fig. 4. Mutant pathogen infection is incurable by the approach displayed in
Fig. 3. A collection of several Pareto fronts for various treatment times T (h),
see inset, using the same parameters as in Figs. 2 and 3. This includes use of
the same initial conditions as in the wild-type (which are not the equilibrium
conditions from (8) to allow for comparison); only a = 10−3 h−1, b =
10−5 h−1 are altered to describe the hipQ-variant of E. coli instead of its
wild-type [13].
When our simplifying assumption that persisters are entirely
resistant to medication is modified, in favor of reduced suscep-
tibility to medication, an extra term of the form “−ω·c(t)·p(t)”
has to be added to the right hand side of (2). With a reasonable
factor of the order of ω ≈ µp/µn (≈0.1 in the case of E. coli
[13]), our model still displays similar generic features for opti-
mal treatments. Regimes still form groups of distinct strategies,
doses for optimal treatment over intermediate lengths T are
still administered early and late. The greatest difference is due
to the greater vulnerability of the bacteria (i.e., their smaller
overall survival rates).
Finally, for other, different conditions and scenarios, such
as modified toxicity behavior, nonlinear dose–response [3]
and modified quality criteria, one can also use multiobjective
optimization to explore and map the pertinent optimality
regimes.
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